Drug Trial Radar · NCT04659031
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
May 25, 2021
Primary completion
Jan 10, 2025
Study completion Jan 10, 2025
Sponsor
- Lead sponsor
- Abcuro, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
Conditions
- Inclusion Body Myositis
Interventions
ABC008Drug
ABC008
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Safety and TolerabilityTime frame: Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Royal Brisbane
Herston, Australia
Perron Institute
Perth, Australia
Royal North Shore Hospital
Sydney, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.